×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Shah Capital ends campaign against Novavax board after Sanofi deal
Yahoo Finance
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation.
2 hours ago
Up 3x In A Week, Will Novavax Stock Continue To See Higher Levels?
Forbes
The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320...
3 days ago
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
The Motley Fool
Vaccine maker Novavax (NVAX -9.65%) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned...
1 day ago
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax's 2024 Annual Meeting
Yahoo Finance
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at...
4 hours ago
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Yahoo Finance
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
3 days ago
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Yahoo Finance
Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned...
1 day ago
Is Novavax Stock a Buy?
The Motley Fool
Novavax (NVAX -9.65%) has been a highly volatile stock in recent years, and that volatility is on full display again this month.
2 days ago
Could Novavax Become the Next Moderna?
The Motley Fool
Novavax (NVAX -9.65%) and Moderna (MRNA 0.17%) both entered the coronavirus vaccine race around the same time, in early pandemic days,...
3 days ago
Novavax (NVAX) Shares Soar on $1.2 Billion Sanofi Vaccine Licensing Deal
Bloomberg
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined...
1 week ago
Sanofi licensing deal doubles value of vaccine group Novavax
Financial Times
Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise the struggling Covid-19 vaccine...
1 week ago